Obesity drug market share is won or lost at the PBM formulary gate.
Even the most clinically advanced metabolic therapies cannot scale successfully without establishing preferred, low-restriction placement on major PBM commercial formularies.
The same conclusion keeps arriving from across the workspace's research — 2 topics independently instantiate this theme. Filter the evidence by where it came from:
A slow retail rollout is directly tied to early-stage PBM coverage bottlenecks, illustrating that commercial viability is gatekept at the formulary level.
A single PBM formulary decision erased Novo's exclusivity advantage overnight, proving market share turns on gatekeeper placement, not clinical data.
The massive initial script gap between Novo's Wegovy pill and Lilly's Foundayo is directly attributed to PBM formulary coverage delays.
Formulary placement across all three largest PBMs converts Lilly's clinical position into dominant insured-patient share.